Clinical outcomes of patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors (mTOR) after immuno-oncology checkpoint inhibitors. - Graham, J
ESMO 2018, Abstract 889 P